Rang	Name	Position
1	Dr. David Apelian M.B.A., M.D., Ph.D.	CEO & Director
2	Dr. Jeffrey S. Glenn M.D., Ph.D.	Scientific Founder & Independent Director
3	Mr. William G. Kaichoff CPA	CFO and Principal Financial & Accounting Officer
4	Mr. Christopher A. Kurtz	Chief Technical Officer
5	Mr. James Vollins J.D.	General Counsel, Chief Compliance Officer & Corporate Secretary
6	Dr. Colin Hislop M.D., MBBS	Senior Vice President of Clinical & Development Operations
7	Dr. Colleen Craig M.D.	Senior Vice President of Metabolic Diseases

Aufteilung der Investoren

Rang	Inhaber	Anteile	Wert
1	Ameriprise Financial Inc	16,89%	0,43 Mio. USD
2	Propel Bio Management LLC	9,89%	0,25 Mio. USD
3	Simplify Asset Management Inc.	6,08%	0,16 Mio. USD
4	Accretive Wealth Partners, LLC	4,26%	0,11 Mio. USD
5	DFPG Investments, Inc.	0,07%	0,00 Mio. USD
6	683 Capital Management LLC	2,00%	0,05 Mio. USD
7	JANE STREET GROUP, LLC	0,07%	0,00 Mio. USD
8	Vanguard Group Inc	1,90%	0,05 Mio. USD
9	BlackRock Inc	1,29%	0,03 Mio. USD
10	Geode Capital Management, LLC	0,85%	0,02 Mio. USD
11	Renaissance Technologies Corp	0,75%	0,02 Mio. USD
12	RBF LLC	0,74%	0,02 Mio. USD
13	Tower Research Capital LLC	0,13%	0,00 Mio. USD
14	Bank of America Corp	0,08%	0,00 Mio. USD
15	Acadian Asset Management LLC	0,07%	0,00 Mio. USD
16	Cutler Group LP	0,00%	0,00 Mio. USD
17	Morgan Stanley - Brokerage Accounts	0,02%	0,00 Mio. USD
18	Royal Bank of Canada	0,02%	0,00 Mio. USD
19	Advisor Group Holdings, Inc.	0,02%	0,00 Mio. USD
20	BNP Paribas Arbitrage, SA	0,01%	0,00 Mio. USD